DE69806042T2 - Phenylalkyl imidazole derivate als h3 rezeptor liganden - Google Patents

Phenylalkyl imidazole derivate als h3 rezeptor liganden

Info

Publication number
DE69806042T2
DE69806042T2 DE69806042T DE69806042T DE69806042T2 DE 69806042 T2 DE69806042 T2 DE 69806042T2 DE 69806042 T DE69806042 T DE 69806042T DE 69806042 T DE69806042 T DE 69806042T DE 69806042 T2 DE69806042 T2 DE 69806042T2
Authority
DE
Germany
Prior art keywords
use according
treatment
histamine
compound
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69806042T
Other languages
German (de)
English (en)
Other versions
DE69806042D1 (de
Inventor
G. Aslanian
D. Mccormick
Mutahi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE69806042D1 publication Critical patent/DE69806042D1/de
Application granted granted Critical
Publication of DE69806042T2 publication Critical patent/DE69806042T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69806042T 1997-11-07 1998-11-05 Phenylalkyl imidazole derivate als h3 rezeptor liganden Expired - Fee Related DE69806042T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96634497A 1997-11-07 1997-11-07
US12971198A 1998-08-05 1998-08-05
PCT/US1998/023223 WO1999024405A1 (en) 1997-11-07 1998-11-05 H3 receptor ligands of the phenyl-alkyl-imidazoles type

Publications (2)

Publication Number Publication Date
DE69806042D1 DE69806042D1 (de) 2002-07-18
DE69806042T2 true DE69806042T2 (de) 2003-01-23

Family

ID=26827847

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69806042T Expired - Fee Related DE69806042T2 (de) 1997-11-07 1998-11-05 Phenylalkyl imidazole derivate als h3 rezeptor liganden

Country Status (17)

Country Link
EP (1) EP1028947B8 (enExample)
JP (1) JP2001522835A (enExample)
KR (1) KR20010031724A (enExample)
CN (1) CN1130349C (enExample)
AR (1) AR016672A1 (enExample)
AT (1) ATE219062T1 (enExample)
AU (1) AU1296699A (enExample)
CA (1) CA2308586A1 (enExample)
CO (1) CO5011065A1 (enExample)
DE (1) DE69806042T2 (enExample)
ES (1) ES2174510T3 (enExample)
HU (1) HUP0004292A3 (enExample)
IL (1) IL135729A0 (enExample)
NZ (1) NZ504124A (enExample)
PE (1) PE134399A1 (enExample)
TW (1) TW421645B (enExample)
WO (1) WO1999024405A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
EP1373251A2 (en) 2001-03-13 2004-01-02 Schering Corporation Non-imidazole compounds as histamine h3 antagonists
PL374758A1 (en) * 2002-10-24 2005-10-31 Merck Patent Gmbh Methylene urea derivatives
WO2006076706A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
EP1749523A1 (en) * 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
WO2007035703A1 (en) 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist
AU2013307688A1 (en) * 2012-08-29 2015-04-09 Merck Patent Gmbh Ddr2 inhibitors for the treatment of osteoarthritis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
NZ330898A (en) * 1993-11-15 2000-01-28 Schering Corp Phenyl-alkyl imidazoles as H3-receptor antagonists in particular for the treatment of inflammation
FR2732017B1 (fr) * 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
PL191073B1 (pl) * 1996-08-16 2006-03-31 Schering Corp Zastosowanie kombinacji antagonistów receptorów histaminowych H1 i H3

Also Published As

Publication number Publication date
HUP0004292A2 (hu) 2001-11-28
EP1028947B1 (en) 2002-06-12
DE69806042D1 (de) 2002-07-18
CA2308586A1 (en) 1999-05-20
NZ504124A (en) 2002-10-25
KR20010031724A (ko) 2001-04-16
WO1999024405A1 (en) 1999-05-20
CN1285822A (zh) 2001-02-28
ES2174510T3 (es) 2002-11-01
TW421645B (en) 2001-02-11
HK1025968A1 (en) 2000-12-01
JP2001522835A (ja) 2001-11-20
EP1028947B8 (en) 2004-01-28
CO5011065A1 (es) 2001-02-28
CN1130349C (zh) 2003-12-10
ATE219062T1 (de) 2002-06-15
EP1028947A1 (en) 2000-08-23
AR016672A1 (es) 2001-07-25
HUP0004292A3 (en) 2001-12-28
AU1296699A (en) 1999-05-31
PE134399A1 (es) 2000-01-10
IL135729A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
DE69432263T2 (de) Phenylalkyl-imidazole als h3-rezeptor-antagonisten
DE69205287T2 (de) Imidazolylalkyl- piperazin und -diazepin derivate als histamin h3 agonisten/antagonisten.
DE602004009294T2 (de) Benzimidazol- und imidazopyridin-derivate mit einer affinität zur melanocortin-rezeptoren zur verwendung als medikamente
DE69617665T2 (de) Benzmidazolverbindungen und ihre verwendung als modulatoren des gabaa-rezeptor-komplexes
DE60115937T2 (de) Piperidinverbindungen zur verwendung als antiallergika
DE60012223T2 (de) Harnstoffderivate wirksam als muscarinrezeptor-antagonisten
US6211182B1 (en) Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
US5990147A (en) H3 receptor ligands of the phenyl-alkyl-imidazoles type
DE69922528T2 (de) N-imidazolyl-alkyl substituierte cyklische amine als histamin-h3 agonisten oder antagonisten
DE69609413T2 (de) BENZIMIDAZOLVERBINDUNGEN UND IHRE VERWENDUNG ALS MODULATOREN DES GABAa-REZEPTORKOMPLEXES
EP0772604A1 (de) Triazolverbindungen und deren verwendung als dopamin-d 3?-liganden
DE69811110T2 (de) Phenyl-alkyl imidazole als h3 rezeptor antagonisten
DE69806042T2 (de) Phenylalkyl imidazole derivate als h3 rezeptor liganden
EP0280873A1 (de) Neue Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE69310904T2 (de) Verbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung
DE3856387T2 (de) 1,2,3,4,10,14b-HEXAHYDRODIBENZO-c,f]PYRAZINO-1,2-a]AZEPINO-DERIVATE
DE60010126T2 (de) Verzweigte substituierte aminoderivate vom 3-amino-1-phenyl-1h(1,2,4)triazol, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE60107586T2 (de) Substituierte imidazole als duale histamine h1 und h3 agonisten oder antagonisten
DE10036818A1 (de) Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
DD283996A5 (de) Verfahren zur herstellung von aminoderivaten
DD282457A5 (de) Verfahren zur herstellung neuer heterocyclischer derivate
DE69303605T2 (de) Unverbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung
DE69910574T2 (de) Pyrazolo[1,5-a]triazine als crf antagonisten
DE60133014T2 (de) Substituierte imidazole als duale histamin h1 und h3 agonisten oder antagonisten
DE69804332T2 (de) Verwendung von somatostatin agonisten und antagonisten zur behandlung von augenkrankheiten

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: ASLANIAN, ROBERT G., ROCKAWAY, N.J., US

8339 Ceased/non-payment of the annual fee